Cadence Pharmaceuticals Announces Addition of OFIRMEV Injection to U.S. Military's Joint Deployment Formulary

Cadence Pharmaceuticals, Inc. CADX announced today that OFIRMEV® (acetaminophen) injection has been added to the U.S. Department of Defense's Joint Deployment Formulary, the core list of pharmaceutical products required for theater-level care of deployed forces. The U.S. Food and Drug Administration approved OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics (pain relievers), and the reduction of fever. The JDF serves as a baseline deployment formulary to treat the most common wounds or diseases that may affect U.S. Armed Forces members. Through its inclusion on the JDF, OFIRMEV is now available for use in deployed theaters by all four U.S. military service branches.